TITLE

Mobilizace krvetvorných buněk pomocí plerixaforu - zkušenosti transplantačních center v České republice

AUTHOR(S)
Kořístek, Z.; Pohlreich, D.; Lysák, D.; Lánská, M.; Novák, J.; Kepák, T.; Skoumalová, I.; Mužík, J.
PUB. DATE
March 2012
SOURCE
Transfusiology & Haematology Today / Transfuze a Hematologie Dne;Mar2012, Vol. 18 Issue 1, p6
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Plerixafor is a novel kind of drug which administration leads to a hematopoietic stem and progenitor cells (HSC) mobilization independently of chemotherapy or G-CSF. Plerixafor is a small molecule bicyclam derivate and inhibits reversibly the SDF-1/CXCR4 interaction, which belongs to the most important mechanisms binding HSC to the bone marrow microenvironment. Inhibition of SDF-1/CXCR4 interaction results in a fast mobilization of HSC into a peripheral blood. Plerixafor is a very valuable substance especially for patients who are not able to mobilize sufficient numbers of HSC after G-CSF ± chemotherapy and, therefore, who are not the candidates for autologous peripheral blood stem cells (PBSC) transplantation because they are not able to collect adequate transplants. The aim of this study is to evaluate results reached with plerixafor in transplant centres in Czech Republic. Patients and methods: Plerixafor was given between 2/2009 and 8/2011 to 93 patients of age from 4 months to 71 years (63% males, 37% females), who were assessed to be proven (failed previous or current mobilization attempt; 82%) or predicted (high risk of failed mobilization; 13.5%) poor mobilizers. Results: The primary objective to collect a safe transplant (≥ 2x106 CD34+ cells/kg) was reached in 71.6% of mobilizations. Plerixafor adverse events were mild and well tolerated. Overall, 66 patients (71.0%) were treated by 69 transplantations using collected PBSC, engraftment was fast and durable. Conclusion: We conclude that plerixafor is a very efficient mobilization agent which allows collecting safe PBSC transplants of a good quality without significant adverse events in a majority of patients who failed standard mobilization. Plerixafor administration enables these patients to proceed to high dose therapy with autologous transplantation, which could significantly improve their prognosis or have a curative effect in certain patients.
ACCESSION #
77227093

 

Related Articles

  • An update on allogeneic hematopoietic progenitor cell transplantation for myeloproliferative neoplasms in the era of tyrosine kinase inhibitors. Adekola, K; Popat, U; Ciurea, S O // Bone Marrow Transplantation;Nov2014, Vol. 49 Issue 11, p1352 

    Myeloproliferative neoplasms are a category of diseases that have been traditionally amenable to allogeneic hematopoietic progenitor cell transplantation. Current developments in drug therapy have delayed transplantation for more advanced phases of the disease, especially for patients with CML,...

  • Emerging Stem Cell Therapies: Treatment, Safety, and Biology. Joel Sng; Thomas Lufkin // Stem Cells International;2012, p1 

    Stem cells are the fundamental building blocks of life and contribute to the genesis and development of all higher organisms. The discovery of adult stem cells has led to an ongoing revolution of therapeutic and regenerative medicine and the proposal of novel therapies for previously terminal...

  • Allogeneic hematopoietic cell transplantation for mycosis fungoides and Sezary syndrome. Lechowicz, M J; Lazarus, H M; Carreras, J; Laport, G G; Cutler, C S; Wiernik, P H; Hale, G A; Maharaj, D; Gale, R P; Rowlings, P A; Freytes, C O; Miller, A M; Vose, J M; Maziarz, R T; Montoto, S; Maloney, D G; Hari, P N // Bone Marrow Transplantation;Nov2014, Vol. 49 Issue 11, p1360 

    We describe outcomes after allogeneic hematopoietic cell transplantation (HCT) for mycosis fungoides and Sezary syndrome (MF/SS). Outcomes of 129 subjects with MF/SS reported to the Center for the International Blood and Marrow Transplant from 2000-2009. Median time from diagnosis to transplant...

  • Hematopoietic SCT for the Black African and non-Black African variants of sickle cell anemia. Lucarelli, G; Isgrò, A; Sodani, P; Marziali, M; Gaziev, J; Paciaroni, K; Gallucci, C; Cardarelli, L; Ribersani, M; Alfieri, C; De Angelis, G; Armiento, D; Andreani, M; Testi, M; Amato, A; Akinyanju, O O; Wakama, T T // Bone Marrow Transplantation;Nov2014, Vol. 49 Issue 11, p1376 

    Sickle cell anemia (SCA) remains associated with high risks of morbidity and early death. Allogeneic hematopoietic SCT (HSCT) is the only curative treatment for SCA. We report our experience with transplantation in a group of patients with the non-Black African variant and the Black African...

  • Emerging concepts for the in vitro derivation of murine haematopoietic stem and progenitor cells. Garcia-Alegria, Eva; Menegatti, Sara; Batta, Kiran; Cuvertino, Sara; Florkowska, Magdalena; Kouskoff, Valerie // FEBS Letters;Nov2016, Vol. 590 Issue 22, p4116 

    Well into the second decade of the 21st century, the field of regenerative medicine is bursting with hopes and promises to heal young and old. The bespoken generation of cells is thought to offer unprecedented cures for a vast range of diseases. Haematological disorders have already benefited...

  • Rapid Multiplex Genotyping of 20 HLA-A*02:01 Restricted Minor Histocompatibility Antigens. Romaniuk, Dmitrii S.; Postovskaya, Anna M.; Khmelevskaya, Alexandra A.; Malko, Dmitry B.; Efimov, Grigory A. // Frontiers in Immunology;6/4/2019, pN.PAG 

    A subset of MHC-associated self-peptides presented by the recipient's cells and immunologically foreign to the donor can induce an allogeneic immune response after hematopoietic stem cell transplantation (HSCT). These immunogenic peptides originate from the genomic polymorphisms and are known as...

  • Two Cases of Successful Autologous Hematopoietic Stem Cell Harvest after Treatment with Brentuximab Vedotin. Kojima, Minoru; Ogiya, Daisuke; Kawai, Hidetsugu; Miyamoto, Mitsuki; Ohmachi, Ken; Ogawa, Yoshiaki; Nakamura, Naoya; ando, Kiyoshi // Acta Haematologica;Sep2015, Vol. 134 Issue 3, p181 

    No abstract available

  • Clinical Characteristics And Outcome Of Biphenotypic Acute Leukemia: 10 Case Reports And Literature Review. Yu, Jifeng; Li, Yingmei; Xing, Haizhou; Pan, Yue; Sun, Hui; Wan, Dingming; Liu, Yanfang; Xie, Xinsheng; Wang, Chong; Sun, Ling; Sun, Kai; Jiang, Zhongxing // Cancer Management & Research;Oct2019, Vol. 11, p9297 

    Background: Biphenotypic acute leukemia (BAL), or mixed-phenotype acute leukemia (MPAL) represents a rare subgroup of acute leukemia which co-expresses markers for either more than one lineage in a homogenous blast population or the coexistence of two blast populations of different lineages....

  • Is it time to revisit our current hematopoietic progenitor cell quantification methods in the clinic? Beksac, M; Preffer, F // Bone Marrow Transplantation;Nov2012, Vol. 47 Issue 11, p1391 

    In the clinical practice of hematopoietic SCT, the minimum numbers of cells required for a successful engraftment are defined on the basis of their CD45 and CD34 expression profiles. However, the quantity of earlier progenitors or CD34-positive cells at different differentiation stages within...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics